What are the limitations of the khorana score?

While the khorana score is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the khorana score to ensure safe bedside use and optimal diagnostic accuracy.

How does the khorana score compare to other Oncology scores?

The khorana score is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the khorana score free to use?

Yes. OpiCalc provides the khorana score completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

Khorana Score

Toxicity, Dosing & Supportive Care

VTE risk score in ambulatory chemotherapy patients.

Primary site risk

Platelets

Hemoglobin

Erythropoiesis-stimulating agent use

Leukocytes

BMI

Waiting For Required Inputs

Complete the required fields to generate the oncology interpretation.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

VTE risk score in ambulatory chemotherapy patients.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Primary site risk

Platelets

Hemoglobin

Erythropoiesis-stimulating agent use

Leukocytes

BMI

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

VTE risk score in ambulatory chemotherapy patients.

OpiCalc Medical Oncology ModuleToxicity, Dosing & Supportive Care2026

CLINICAL INSIGHT

Background

Context

Khorana Score is included in the oncology module as a structured decision-support tool for toxicity, dosing & supportive care workflows.

No clinical reference data available.

Khorana Score

Toxicity, Dosing & Supportive Care

VTE risk score in ambulatory chemotherapy patients.

Primary site risk

Platelets

Hemoglobin

Erythropoiesis-stimulating agent use

Leukocytes

BMI

Waiting For Required Inputs

Complete the required fields to generate the oncology interpretation.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

VTE risk score in ambulatory chemotherapy patients.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Primary site risk

Platelets

Hemoglobin

Erythropoiesis-stimulating agent use

Leukocytes

BMI

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

VTE risk score in ambulatory chemotherapy patients.

OpiCalc Medical Oncology ModuleToxicity, Dosing & Supportive Care2026

CLINICAL INSIGHT

Background

Context

Khorana Score is included in the oncology module as a structured decision-support tool for toxicity, dosing & supportive care workflows.

No clinical reference data available.